argenx stock

ARGX · Euronext Brussels · EUR

Secondary listing. The primary listing is argenx · NASDAQ (USD)

€879.60Change from previous close: +0.14%Absolute change: +€1.20

Close · November 16, 2026

Price history

+11.00% over the period

1 year: from €792.40 (November 17, 2025) to €879.60 (November 16, 2026), +11.00%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026€879.60
October 30, 2026€807.20
September 30, 2026€846.80
August 31, 2026€875.60
July 31, 2026€745.00
June 30, 2026€811.40
May 29, 2026€715.60
April 30, 2026€668.00
March 31, 2026€620.80
February 27, 2026€657.40
January 30, 2026€703.80
December 31, 2025€716.80
November 28, 2025€782.40
November 17, 2025€792.40

At a glance

  • The company

    Commercial-stage biopharma company developing therapies for autoimmune diseases including gMG, ITP, CIDP and other conditions

  • Latest results

    Quarter to September 30, 2026 · EPS $6.97 (estimate $7.02)

TickerLandia's take on argenx

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€568.40
52-wk high€925.00

−4.91% from the 52-week high

Analysts · 15 analysts

Average target€1,014.93+15.39% vs. price

Buy 13 · Hold 2 · Sell 0 · Strong buy

TickerLandia Fingerprint: argenx

Compared with similar companies: very high financial strength and very high growth.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

argenx is in line with similar companies

argenx's P/E (trailing 12 months): 35.3, in line with the median of a group of 7 similar companies (34.7).

Compared with 7 similar companies

argenx's metrics compared with similar companies
MetricargenxPosition in the groupBand
P/E (trailing 12 months)35.3Middle
Forward P/E27.4Middle
Operating margin31.9%Middle
ROE23.6%High
Debt/equity0.01Low

Grey band: the middle half of the group; tick: the median; dot: argenx. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.75B

Latest quarter · Q3 2026

Net income

$506M

Latest quarter · Q3 2026

Quarterly net margin

28.9%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
€55.24B
P/E
35.3
EPS
€24.85
Volume
64.68K
Daily trading
€76.66M
Dividend yield
0.00%

How argenx is changing

All results
  • Revenue grew 152.5% a year on average over the last 5 years

  • Operating margin rose from −7,184.7% to 24.9%

  • Less cash than profit: free cash flow equal to 9% of net income

Returns

argenx returns

€1,000 invested in argenx 5 years ago, on November 16, 2021, would be worth €3,328 today: +232.80% in total, +27.19% per year. This is the price return only: dividends are excluded.

PeriodargenxEURO STOXX 50€1,000 becomes
1 month+20.89%+3.56%€1,209
6 months+26.89%+9.59%€1,269
Year to date+22.71%+10.19%€1,227
1 year+11.00%+13.22%€1,110
3 years+95.47%+48.45%€1,955
5 years+232.80%+45.11%€3,328
10 years+6,415.56%+111.04%€65,156

Over the last 6 months it has done better than 51% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

argenx: technical analysis

argenx is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.6% below its all-time closing high (€912.40, September 3, 2026).

Trend
Upward
RSI (14 sessions)
67
Between 30 and 70
vs 200-session average
+17.16%

Support and resistance

Price areas where argenx has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price€879.60
  3. Support€832.70−5.33%4 touches, last on September 24, 2026
  4. Support€737.00−16.21%5 touches, last on July 17, 2026
  5. Support€719.16−18.24%5 touches, last on August 14, 2026

Volatility and risk

Over the last year it has moved little with the EURO STOXX 50.

Beta (1 year) vs EURO STOXX 50
0.38
Volatility (60 sessions, annualised)
46.9%
Largest fall in the last year
−27.37%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

argenx: seasonality

Average monthly price change over 13 years

−0.1%Jan+2.5%Feb+0.2%Mar+4.2%Apr+6.1%May+4.7%Jun+7.4%Jul+2.6%Aug−1.4%Sep+1.1%Oct+8.6%Nov+11.7%Dec

Over the last 13 years, the strongest month for argenx has been December: +11.66% on average, positive in 8 years out of 12. The weakest has been September: −1.38% on average, positive in 6 years out of 13. November, the current month, has been positive in 9 years out of 12 (+8.64% on average).

Show chart data
MonthAverageMedianPositive years
January−0.13%+0.02%6 of 12
February+2.45%−1.49%5 of 12
March+0.18%+0.80%6 of 12
April+4.18%+3.19%10 of 12
May+6.07%+5.31%7 of 12
June+4.68%+1.78%6 of 12
July+7.41%+5.32%8 of 12
August+2.60%+1.71%8 of 13
September−1.38%−0.90%6 of 13
October+1.07%−0.23%6 of 13
November+8.64%+7.03%9 of 12
December+11.66%+2.65%8 of 12

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

argenx and its competitors

Based in Amsterdam, the Netherlands, argenx SE was incorporated in 2008 and operates as a commercial-stage biopharmaceutical company focused on autoimmune diseases. Its marketed medicines include VYVGART for generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).

Headquarters
Amsterdam, Netherlands
Employees
1,863
Founded
2008
Chief executive
Karen Massey
argenx and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
argenxARGX$61.05B31.9%35.3+26.89%
BeOne MedicinesONC$47.58B17.8%53.4+31.59%
ModernaMRNA$90.38B-80.8%—+343.02%
Royalty PharmaRPRX$39.85B64.4%45.3+30.16%
Revolution MedicinesRVMD$37.27B-853.0%—+14.91%
Regeneron PharmaceuticalsREGN$98.84B30.4%21.1+32.73%

Same industry or related industries, similar size. Compare argenx with its competitors · Full profile